Publication:
Synthesis and biological activities of diflunisal hydrazide-hydrazones

dc.contributor.authorKÜÇÜKGÜZEL, ŞÜKRİYE GÜNİZ
dc.contributor.authorsKucukguzel, SG; Mazi, A; Sahin, F; Ozturk, S; Stables, J
dc.date.accessioned2022-03-12T17:17:32Z
dc.date.accessioned2026-01-11T15:43:32Z
dc.date.available2022-03-12T17:17:32Z
dc.date.issued2003
dc.description.abstractSeveral diflunisal hydrazide-hydrazone derivatives namely 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid [(5-nitro-2-furyl/substitutedphenyl)methylene] hydrazide (3a-o) have been synthesised. Methyl 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylate (1) and 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid hydrazide (2) were also synthesised and used as intermediate compounds. All synthesised compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37 Rv, antimicrobial activities against various bacteria, fungi and yeast species. Compound 3a have shown activity against Staphylococcus epidermis HE-5 and Staphylococcus aureus HE-9 at 18.75 and 37.5 mug mL(-1), respectively. Compound 3o have exhibited activity against Acinetobacter calcoaceticus IO-16 at a concentration of 37.5 mug mL(-1), whereas Cefepime, the drug used as standard, have been found less active against the microorganisms mentioned above. The synthesised compounds were found to provide 12-34% inhibition of mycobacterial growth of M. tuberculosis H37 Rv in the primary screen at 6.25 mug mL-1. Anticonvulsant activity of the compounds were also determined by maximal electroshock (MES) and subcutaneous metrazole (scMET) tests in mice and rats following the procedures of antiepileptic drug development (ADD) program of the National Institutes of Health (NIH). Compound 3k showed 25% protection against MES induced seizures in p.o. rat screening at a dose level of 30 mg kg(-1) whereas 3n and 3o showed neurotoxicity after 4 and 0.5 h at a dose level of 100 and 300 mg kg(-1) respectively. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
dc.identifier.doi10.1016/j.ejmech.2003.08.004
dc.identifier.eissn1768-3254
dc.identifier.issn0223-5234
dc.identifier.pubmed14642333
dc.identifier.urihttps://hdl.handle.net/11424/227860
dc.identifier.wosWOS:000188000400011
dc.language.isoeng
dc.publisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
dc.relation.ispartofEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjecthydrazide-hydrazones
dc.subjectdiflunisal
dc.subjectantibacterial activity
dc.subjectanticonvulsant activity
dc.subjectHETCOR
dc.subjectANTITUBERCULOTIC ACTIVITY
dc.subjectANTICONVULSANT ACTIVITY
dc.subjectDERIVATIVES
dc.subjectACID
dc.subject4-THIAZOLIDINONES
dc.subjectSEMICARBAZONES
dc.subjectPRODUCTS
dc.subjectAGENTS
dc.titleSynthesis and biological activities of diflunisal hydrazide-hydrazones
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage1013
oaire.citation.issue11-12
oaire.citation.startPage1005
oaire.citation.titleEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
oaire.citation.volume38

Files